In particular, it has been demonstrated that rosiglitazone reduces the binding of the SDF 1-α secreted by CAFs to the CXCR4 expressed in MCF-7 and MDA-MB-231 breast cancer cells, thus reducing breast cancer cell motility [7]. This evidence concerns the gene CXCR4 and breast carcinoma.